Trial | NCT04686994  Report issue

Title

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics (Biomarkers) of ASC41 Tables in Overweight and Obese Subjects

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ASC 41 ...

  • Study Participants

    20
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
Study Started
Dec 22
2020
Primary Completion
Jan 19
2021
Study Completion
Feb 07
2021
Last Update
Apr 08
2021

Drug ASC 41

Oral tablets

Drug ASC 41 Placebo

Oral tablets

ASC41 Experimental

ASC41 two tablets, once daily, from Day 1 to Day 28.

ASC41 placebo Placebo Comparator

ASC41 placebo two tablets, once daily, from Day 1 to Day 28.

Criteria 

Key Inclusion Criteria:

23kg/m2 ≤ BMI <40kg/m2.

Key Exclusion Criteria:

A history of thyroid disease.
A positive HBsAg, HCV Ab and/or HIV Ab.
No Results Posted